search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Ketanest in septic shock.


- candidate number5312
- NTR NumberNTR1672
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR16-feb-2009
- Secondary IDs22992/2008-002598-11  ABR/EudraCT
- Public TitleKetanest in septic shock.
- Scientific TitleKetanest in septic shock.
- ACRONYMKISS
- hypothesisWe hypothesise that (restoration of) a adequate circulation in early septic shock is reached sooner and with less vasoactive support and fluid therapy using ketanest.
(Secondary): Furthermore, we hypothesise that adrenal gland is not suppressed following induction of anesthesia with ketanest, in contrast to induction with etomidate.
- Healt Condition(s) or Problem(s) studiedSeptic shock
- Inclusion criteria1. Septic shock (see below);
2. In need for ventilatory support;
3. To be intubated on the ICU.
- Exclusion criteria1. <18 and >80 years old;
2. Symptomatic coronary artery disease;
3. Due to have surgery within 4 hours;
4. Already on corticosteroid therapy;
5. Pregnancy;
6. Pulmonary hypertension;
7. Preterminal illness.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-feb-2009
- planned closingdate1-feb-2010
- Target number of participants20
- InterventionsInvestigational treatment.
Patients accepted for this study are randomised to either the ketanest (K) or etomidate (E) group. The only a priori difference in treatment will be the induction and maintenance agent. The K protocol demands induction with ketanest (1.0 mg/kg) and rocuronium 1.2 mg/kg, followed by maintenance with ketanest (1-3mg/kg/h). The E group is induced with etomidate 0.2 mg/kg and rocuronium 1.2 mg/kg, followed by maintenance with midazolam (4-10 mg/h) and fentanyl (100ug/h). Maintenance doses must be adjusted to individual need. Two hours after induction of anesthesia (i.e. start of the intervention) maintenance with ketanest will be switched to midazolam and fentanyl. Sedation with midazolam and fentanyl must be continued for at least 23 hours in order to prevent adverse psychological effects.
- Primary outcomeThese variables are measured every hour during the first 8 hours. However, these variables will be measured every 10 minutes during:
1. The two hour following the induction of anesthesia (0-2h);
2. The two hour after the switch to midazolam/fentanyl anesthesia (2-4).

1. CVP (10 min average);
2. HR/BP (10 min average);
3. MAP (10 min average);
4. Urine output (60 min average);
5. ScvO2 and arterial blood analysis (every 30 minutes);
6. Resuscitation volume (specific sum);
7. Inotropic support (value of rate and cumulative dose);
8. Vasopressor support (value of rate and cumulative dose).
- Secondary outcome1. Ventilatory and oxygen delivery variables: Airway pressures / FiO2 / tidal volume / Lactate /Hb, are measured every hour during the first 4 hours, and after 8 hours;
2. Adverse psychological reactions: During the observation period, checking the medical record upto 24 hours after induction, and, if possible, asking the patient for adverse psychological effects as soon as possible after awaking and after extubation;
3. Adrenal gland responsiveness: Before induction: basal serum total cortisol, free cortisol, and 11beta-deoxycortisol At 6 and 24 hrs after induction of anesthesia: basal serum total cortisol, free cortisol, and 11beta-deoxycortisol followed by a standard high dose (250 ug of synthetic ACTH) Synacthentest, with measurements of total, free cortisol and 11-beta deoxycortisol at 0, 30 and 60 minutes;
4. Inflammatory markers: Baseline, 6 and 24 hours: IL6, TNFa.
- Timepoints25 hours after induction of anesthesia the observation (study) period ends.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDr. S. Houtman
- CONTACT for SCIENTIFIC QUERIESDr. S. Houtman
- Sponsor/Initiator VU University Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Canisius-Wilhelmina hospital
- PublicationsN/A
- Brief summaryRationale:
In patients with septic shock, most anesthetists are used to induce anesthesia with etomidate, because of its favourable effect on cardiovascular stability. However, awareness of the adverse effects of single induction dose of etomidate on the adrenal gland, and the hemodynamic advantages of ketanest have increased over the last decade. Therefore, induction of anesthesia using ketanest in critically ill patients may be superior compared to etomidate.
Objective:
Compare induction of anesthesia using etomidate or ketanest on hemodynamic consequences and adrenal function in patients with septic shock in need of intubation.
Study design:
prospective single center randomized not-blinded clinical trial.
Study population:
patients admitted to the ICU with septic shock and in need of ventilatory support.
Intervention:
anesthesia is induced with ketanest (1 mg/kg) in the trial group (K), and with etomidate in the control group (E). Sedation is maintained with ketanest (1 mg/kg/h) in the K group and midazolam (10 mg/h) and fentanyl (0.1 mg/h) in the E group during the first 2 hours.
Main study parameters/endpoints:
The primary outcome variables reflect hemodynamics during the first two hours after induction, and following the switch to standard sedation. The secondary outcome variables reflect organ function, the extent of adrenal gland suppression following induction of anesthesia and assessment of psychological side effects.
- Main changes (audit trail)
- RECORD16-feb-2009 - 14-sep-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl